McKesson — May 8, 2025 release

• The Company does not forecast GAAP earnings per diluted share 1 . • Reaffirming long-term Adjusted Earnings per Diluted Share growth target of 12% to 14% and updating long-term Adjusted Segment Operating Profit growth target for U.S. Pharmaceutical from 5% to 7% to a new target of 6% to 8%. 1 See below under "Fiscal 2026 Outlook" for full explanation Strategic Portfolio Update for the Medical-Surgical Solutions Segment Today McKesson is announcing its intention to separate its Medical-Surgical Solutions segment into an independent company ("NewCo"). Disciplined portfolio management is a hallmark of our enterprise strategy. McKesson believes a separation will further enhance the strategic opportunity and operational focus of both companies and unlock value for McKesson shareholders. The separation would advance McKesson and NewCo's ability to create value for customers, partners, patients, and shareholders. With a separation of Medical-Surgical Solutions, McKesson will focus the Company and its capital deployment priorities on opportunities that best align with its long-term enterprise strategies, advancing McKesson's portfolio to focus investment on higher growth, higher margin opportunities in Oncology and Biopharma Solutions, unlocking substantial value for stakeholders. "Disciplined capital deployment and portfolio management are hallmarks of our strategy," said Mr. Tyler. "In alignment with our strategy, we are announcing our intent to separate the Medical-Surgi